Search results for "COMB"

showing 10 items of 7115 documents

An Algorithm Combining Patient Performance Status, Second Hit Analysis, PROVEAN and Dann Prediction Tools Could Foretell Sensitization to PARP Inhibi…

2021

Simple Summary PARP inhibitors, a family of targeted cancer therapeutics, have been shown to be efficient in patients with some deficiencies in the homologous recombination machinery. However, a quick and reliable identification of patients who would benefit from such therapies remains a challenge. In particular, patients with tumors carrying variants of unknown significance (VUS) in homologous recombination genes do not currently benefit from PARP inhibitor treatments. In this study, we present an algorithm that may allow classification of these variants with regard to their impact on tumor responsiveness to PARP inhibitors. If validated on a larger patient sample, our algorithm would allo…

0301 basic medicineCancer ResearchIn silicohomologous recombinationArticleOlaparib03 medical and health scienceschemistry.chemical_compound0302 clinical medicineHomologous chromosomeMedicineProgression-free survivalAllele frequencyPARP inhibitorsSensitizationRC254-282responsePerformance statusbusiness.industryNeoplasms. Tumors. Oncology. Including cancer and carcinogensVUS030104 developmental biologymedicine.anatomical_structureOncologychemistry030220 oncology & carcinogenesisPARP inhibitorbusinessAlgorithmprogression-free survivalCancers
researchProduct

9-ING-41, a small-molecule glycogen synthase kinase-3 inhibitor, is active in neuroblastoma.

2018

Advanced stage neuroblastoma is a very aggressive pediatric cancer with limited treatment options and a high mortality rate. Glycogen Synthase Kinase-3β (GSK-3β) is a potential therapeutic target in neuroblastoma. Using immunohistochemical staining, we observed positive GSK-3β expression in 67% of human neuroblastomas (34 out of 51 cases). Chemically distinct GSK-3 inhibitors (AR-A014418, TDZD8 and 9-ING-41), suppressed the growth of neuroblastoma cells whereas 9-ING-41, a clinically relevant small molecule GSK-3β inhibitor with broad spectrum pre-clinical antitumor activity, being the most potent. Inhibition of GSK-3 resulted in a decreased expression of the antiapoptotic molecule XIAP and…

0301 basic medicineCancer ResearchIndolesMice NudeCell Growth ProcessesIrinotecanArticleMaleimides03 medical and health sciencesMiceNeuroblastoma0302 clinical medicineGSK-3NeuroblastomaCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsmedicineAnimalsHumansPharmacology (medical)Enzyme InhibitorsGlycogen synthasePharmacologyGlycogen Synthase Kinase 3 betabiologyChemistryDrug Synergismmedicine.diseasePediatric cancerXenograft Model Antitumor AssaysXIAP030104 developmental biologyOncologyCell cultureApoptosis030220 oncology & carcinogenesisCancer researchbiology.proteinImmunohistochemistryFemaleAnti-cancer drugs
researchProduct

Tumor-Associated Fibroblasts Promote HER2-Targeted Therapy Resistance through FGFR2 Activation

2020

AbstractPurpose:Despite the therapeutic success of existing HER2-targeted therapies, tumors invariably relapse. This study aimed at identifying new mechanisms responsible for HER2-targeted therapy resistance.Experimental Design:We have used a platform of HER2-targeted therapy–resistant cell lines and primary cultures of healthy and tumor-associated fibroblasts (TAF) to identify new potential targets related to tumor escape from anti-HER2 therapies.Results:We have shown that TAFs promote resistance to HER2-targeted therapies. TAFs produce and secrete high levels of FGF5, which induces FGFR2 activation in the surrounding breast cancer cells. FGFR2 transactivates HER2 via c-Src, leading to res…

0301 basic medicineCancer ResearchReceptor ErbB-2medicine.medical_treatmentMice NudeBreast NeoplasmsDrug resistanceTargeted therapy03 medical and health sciencesMice0302 clinical medicineBreast cancerCancer-Associated FibroblastsTrastuzumabCell Line TumorAntineoplastic Combined Chemotherapy ProtocolsmedicineNeoplasmAnimalsHumansReceptor Fibroblast Growth Factor Type 2skin and connective tissue diseasesneoplasmsbusiness.industryLapatinibTrastuzumabmedicine.diseaseXenograft Model Antitumor AssaysSurvival Rate030104 developmental biologyOncologyTumor EscapeApoptosisDrug Resistance Neoplasm030220 oncology & carcinogenesisCancer researchFemaleSignal transductionNeoplasm Recurrence Localbusinessmedicine.drugSignal Transduction
researchProduct

The role of surgery in platinum-resistant ovarian cancer: A call to the scientific community.

2021

Abstract In the last decade, a growing attention has been focused on identifying effective therapeutic strategies also in the orphan clinical setting of women with platinum-resistant disease. In this context, secondary cytoreductive surgery (SCS) remains a potential approach only in women with platinum sensitive relapse, but experimental data have been published supporting the role of SCS also in patients with platinum-resistant recurrence. In particular, surgery is emerging as a potential option in specific subgroups of women, such as those patients with low-grade serous histology, or low-volume relapse with disease located in the so-called pharmacological sanctuaries. Furthermore, contras…

0301 basic medicineCancer Researchmedicine.medical_specialtymedicine.medical_treatmentContext (language use)Antineoplastic AgentsPlatinum CompoundsDiseaseHyperthermic Intraperitoneal ChemotherapyCarcinoma Ovarian Epithelial03 medical and health sciences0302 clinical medicineMedicineAnimalsHumansIn patientPlatinum resistantChemotherapybusiness.industryCytoreduction Surgical Proceduresmedicine.diseaseCombined Modality TherapySurgerySerous fluid030104 developmental biologyDrug Resistance Neoplasm030220 oncology & carcinogenesisPlatinum sensitiveFemaleNeoplasm Recurrence LocalbusinessOvarian cancerBiological features Minimally invasive surgery Personalized treatment Platinum resistant Recurrent ovarian cancer Secondary cytoreductive surgerySeminars in cancer biology
researchProduct

Tumor Microenvironment And Epithelial Mesenchymal Transition As Targets To Overcome Tumor Multidrug Resistance

2020

It is well established that multifactorial drug resistance hinders successful cancer treatment. Tumor cell interactions with the tumor microenvironment (TME) are crucial in epithelial-mesenchymal transition (EMT) and multidrug resistance (MDR). TME-induced factors secreted by cancer cells and cancer-associated fibroblasts (CAFs) create an inflammatory microenvironment by recruiting immune cells. CD11b+/Gr-1+ myeloid-derived suppressor cells (MDSCs) and inflammatory tumor associated macrophages (TAMs) are main immune cell types which further enhance chronic inflammation. Chronic inflammation nurtures tumor-initiating/cancer stem-like cells (CSCs), induces both EMT and MDR leading to tumor re…

0301 basic medicineCancer Researchmedicine.medical_treatmentMultidrug resistanceTargeted therapyTargeted therapy0302 clinical medicineCancer-Associated FibroblastsNeoplasmsAntineoplastic Combined Chemotherapy ProtocolsTumor-Associated MacrophagesTumor MicroenvironmentPharmacology (medical)HypoxiaTOR Serine-Threonine KinasesSmall moleculesChemotherapy ; Hypoxia ; Inflammation ; Microenvironment ; Multidrug resistance ; Small molecules ; Targeted therapy.Drug Resistance Multiple3. Good healthDNA DemethylationGene Expression Regulation NeoplasticInfectious DiseasesOncology030220 oncology & carcinogenesisInflammation MediatorsEpithelial-Mesenchymal TransitionStromal cellMicroenvironmentBiologyProinflammatory cytokine03 medical and health sciencesCell Line TumormedicineAnimalsHumansChemotherapyEpithelial–mesenchymal transitionPharmacologyInflammationTumor microenvironmentCancerHypoxia-Inducible Factor 1 alpha Subunitmedicine.diseaseHistone Deacetylase InhibitorsMultiple drug resistanceDisease Models Animal030104 developmental biologyDrug Resistance NeoplasmCancer cellCancer research
researchProduct

Improved display of synthetic IgG-binding domains on the baculovirus surface.

2004

Improved display of foreign protein moieties in combination with beneficial alteration of the viral surface properties should be of value for targeted and enhanced gene delivery. Here, we describe a vector based on Autographa californica multiple nucleopolyhedrovirus (AcMNPV) displaying synthetic IgG-binding domains (ZZ) of protein A fused to the transmembrane anchor of vesicular stomatitis virus (VSV) G protein. This display vector was equipped with a GFP/EGFP expression cassette enabling fluorescent detection in both insect and mammalian cells. The virus construct displayed the biologically active fusion protein efficiently and showed increased binding capacity to IgG. As the display is …

0301 basic medicineCancer ResearchvirusesRecombinant Fusion Proteins030106 microbiologyGenetic VectorsGene deliveryBiologySpodopteraVesicular stomatitis Indiana virusViral vectorCell Line03 medical and health sciencesViral Envelope ProteinsViral entryCricetinaeAnimalsMembrane GlycoproteinsImmune SerafungiGenetic Therapybiology.organism_classificationMolecular biologyFusion proteinNucleopolyhedroviruses030104 developmental biologyOncologyIgG bindingVesicular stomatitis virusImmunoglobulin Gbiology.proteinExpression cassetteBinding Sites AntibodyRabbitsProtein ABaculoviridaeTechnology in cancer researchtreatment
researchProduct

Ceftazidime-Avibactam Combination Therapy Compared to Ceftazidime-Avibactam Monotherapy for the Treatment of Severe Infections Due to Carbapenem-Resi…

2020

Ceftazidime-avibactam (CZA) is a novel beta-lactam beta-lactamase inhibitor combination approved for the treatment of complicated urinary tract infections, complicated intra-abdominal infections, and for hospital-acquired/ventilator-associated pneumonia. The aim of this systematic review (PROSPERO registration number: CRD42019128927) was to evaluate the effectiveness of CZA combination therapy versus CZA monotherapy in the treatment of severe infections. The databases included in the search, until February 12th, 2020, were MEDLINE by PubMed, EMBASE, and The Cochrane Central Register of Controlled Trials. We included both randomized controlled trials (RCTs) and non-randomized studies publish…

0301 basic medicineCarbapenem-resistant enterobacteriaceaeBiochemistrylaw.inventionsepsisCeftazidime‐avibactam0302 clinical medicineRandomized controlled trialsystematic reviewlawPharmacology (medical)030212 general & internal medicineGeneral Pharmacology Toxicology and Pharmaceuticsnetwork meta-analysisceftazidime-avibactamAnti‐infective agentnetwork meta-analysiInfectious Diseasescarbapenem-resistant EnterobacteriaceaeMeta-analysisβ-lactamase inhibitors.sepsimedicine.drugMicrobiology (medical)medicine.medical_specialtyCombination therapyβ-lactamase inhibitors030106 microbiologyMEDLINEβ‐lactamase inhibitorsMicrobiologyArticle03 medical and health sciencesCarbapenem‐resistant Enterobacteriaceaemultidrug resistanceInternal medicinemedicineanti-infective agentbacteremiabusiness.industrylcsh:RM1-950Retrospective cohort studyCeftazidime/avibactammedicine.diseaseinfectionlcsh:Therapeutics. PharmacologyBacteremiaanti-infective agentsbusinessNetwork meta‐analysi
researchProduct

Chondroprotective effects of the combination chondroitin sulfate-glucosamine in a model of osteoarthritis induced by anterior cruciate ligament trans…

2016

[EN] Context: The efficacy of the combination chondroitin sulfate-glucosamine (CS-GlcN) in the treatment of knee osteoarthritis (OA) has been suggested in recent clinical studies. In vitro reports have also suggested anti-inflammatory and anti-resorptive effects of this combination. Objective: The aim of this study was to characterize the effects of CS-GlcN on joint degradation in vivo including the assessment of inflammation and bone metabolism in a model of OA. Materials and methods: We have used the OA model induced by anterior cruciate ligament transection (ACLT) in ovariectomised rats. CS-GlcN was administered daily (oral gavage) from week 0 until week 12 after ovariectomy at the dose …

0301 basic medicineCartilage Articularmedicine.medical_specialtyAnterior cruciate ligamentOvariectomyType II collagenOsteoarthritisProtective AgentsBone and BonesBone remodeling03 medical and health scienceschemistry.chemical_compound0302 clinical medicineOsteoprotegerinGlucosamineInternal medicineOsteoarthritisMedicineAnimalsChondroitin sulfateAnterior cruciate ligament transectionAnterior Cruciate LigamentRats Wistar030203 arthritis & rheumatologyPharmacologyGlucosaminebusiness.industryCartilageAnterior Cruciate Ligament InjuriesChondroitin SulfatesGeneral MedicineX-Ray MicrotomographyOsteoarthritis Kneemedicine.diseaseChondroitin sulfate-glucosamine Ovariectomised ratscarbohydrates (lipids)Disease Models Animal030104 developmental biologymedicine.anatomical_structureEndocrinologychemistryDrug Therapy CombinationFemaleJointsInflammation MediatorsbusinessBiomarkersModel
researchProduct

Few layer 2D pnictogens catalyze the alkylation of soft nucleophiles with esters

2019

Group 15 elements in zero oxidation state (P, As, Sb and Bi), also called pnictogens, are rarely used in catalysis due to the difficulties associated in preparing well–structured and stable materials. Here, we report on the synthesis of highly exfoliated, few layer 2D phosphorene and antimonene in zero oxidation state, suspended in an ionic liquid, with the native atoms ready to interact with external reagents while avoiding aerobic or aqueous decomposition pathways, and on their use as efficient catalysts for the alkylation of nucleophiles with esters. The few layer pnictogen material circumvents the extremely harsh reaction conditions associated to previous superacid–catalyzed alkylations…

0301 basic medicineCatàlisi heterogèniaScienceFOS: Physical sciencesGeneral Physics and Astronomy02 engineering and technologyAlkylationIonic liquidGeneral Biochemistry Genetics and Molecular BiologyArticleCatalysis03 medical and health scienceschemistry.chemical_compoundNucleophileOxidation stateAntimonenePhysics - Chemical PhysicsQUIMICA ANALITICAlcsh:ScienceMaterialsChemical Physics (physics.chem-ph)MultidisciplinaryAqueous solutionChemistryPnictogensPhosphoreneQGeneral Chemistry021001 nanoscience & nanotechnologyCombinatorial chemistryPhosphorene030104 developmental biologyReagentddc:540Ionic liquidlcsh:QCatalyst0210 nano-technologyNature Communications
researchProduct

Cytotoxic effects induced by patulin, deoxynivalenol and toxin T2 individually and in combination in hepatic cells (HepG2).

2018

Abstract Patulin (PAT), deoxynivalenol (DON) and toxin T-2 (T-2) are mycotoxins distributed worldwide in food and feed. Cytotoxicity of the three mycotoxins individually or in combination in human hepatocellular carcinoma (HepG2) cells was evaluated by MTT assay over 24, 48 and 72 h of exposure. The concentration ranges used were 0.625–15 μM for DON, 1.25–50 nM for T-2 and 0.45–7.5 μM for PAT. The IC 50 values obtained ranged from 9.30 to 2.53 μM, from 33.69 to 44.37 nM and from 2.66 to 1.17 μM for DON, T-2 and PAT, respectively. The most cytotoxic mycotoxin to HepG2 cells was T-2 followed by PAT and DON. The combination ratios used for the mixtures were 1:3 (DON: T-2), 1:5 (DON: PAT), 1:1.…

0301 basic medicineCell SurvivalComplex MixturesToxicologymedicine.disease_causePatulin03 medical and health scienceschemistry.chemical_compoundInhibitory Concentration 500404 agricultural biotechnologymedicineCytotoxic T cellHumansMTT assayDrug InteractionsCytotoxicityMycotoxinDose-Response Relationship DrugToxin04 agricultural and veterinary sciencesGeneral MedicineHep G2 CellsMycotoxinsmedicine.disease040401 food scienceMolecular biologyDrug CombinationsT-2 Toxin030104 developmental biologyPatulinchemistryLiverHepatocellular carcinomaHepatic stellate cellTrichothecenesFood ScienceFood and chemical toxicology : an international journal published for the British Industrial Biological Research Association
researchProduct